Skip to main content

NextCure, Inc.

NXTC
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001661059

In the last 90 days, NextCure, Inc. insiders filed 2 open-market purchases and 1 sale; 30 institutions reported holding it in 13F filings for Q2 2026, worth $2.78M in total; no superinvestor holds it.

Q3 2024 vs. Q2 2024

How the institutions holding NextCure, Inc. changed between Q2 2024 and Q3 2024.

All holders in Q3 2024All holders in Q2 2024

13F holders of NXTC: Q2 2024 compared with Q3 2024
MeasureQ2 2024Of which not filed for Q3 2024Q3 2024Change
Holders49144−4
Shares16.0M761.2K15.9M+616.2K (+4.0%)
Value$25.5M$1.21M$21.7M−$2.51M (−10.4%)

1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (3)

Institutions that held NextCure, Inc. at the end of Q3 2024 but not at the end of Q2 2024.

Institutions new to NXTC in Q3 2024
InstitutionSharesValue% of portfolio
BlackRock, Inc.729,836$999.9K0.00%
Engineers Gate Manager LP10,774$14.8K0.00%
Advisor Group Holdings, Inc.1,191$1.63K0.00%

Sold out (7)

Institutions that held NextCure, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.

Institutions that sold out of NXTC in Q3 2024
InstitutionShares, Q2 2024Value, Q2 2024
XTX Topco Ltd20,874$33.2K
Jane Street Group, LLC19,342$30.8K
Tower Research Capital LLC (TRC)1,227$1.95K
Rhumbline Advisers703$1.12K
Royal Bank of Canada403$1.00K
Qube Research & Technologies Ltd48$76
Simplex Trading, LLC547$0

Not filed for Q3 2024 yet (1)

Institutions that held NextCure, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding NXTC in Q2 2024 that haven't filed for Q3 2024
InstitutionShares, Q2 2024Value, Q2 2024
BlackRock Inc.761,180$1.21M